DOCSLIB.ORG

FACT SHEET Pcpp

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

FACT SHEET pCPP September 2016 For more information, please contact: Dr. P. Blanckaert Coordinator Belgian Early Warning System Drugs Scientific Institute of Public Health National Focal Point on Drugs Jyliette Wytsmanstraat 14 B-1050 Brussels, Belgium Tel : 02/642 5408 [email protected] Science at the service of Public health, Food chain safety and Environment. The information in this message is exclusively meant for the EWS-network, and was sent to you, as a member of this network, in a confidential way. Therefore the information in this message may not be copied, transferred or made public without the prior permission of the WIV-ISP. The WIV-ISP takes responsibility for the editing of a press release, if considered as necessary in the framework of its mission. The information contained in this document is also available on the BEWSD-website (with corresponding pdf-files and analytical data). This part of the website is not accessible for the general public. A login can be requested by contacting [email protected]. © Scientific Institute of Public Health, Brussels 2016 This report may not be reproduced, published or distributed without the consent of the ISP | WIV. A. General information Recent collected sample in Belgium Substance: pCPP mixture with amphetamines Date of Collection: August 2016 Date of analysis: September 2016 Color: Pink Region: Brussels Diameter: 8mm Thickness: 5mm Tablet weight: 230 mg Created September 2016 Updated / Type Psychotropic Substances Group Piperazine Derivates Name p-Chlorophenylpiperazine (pCPP) Nature of substance pCPP is a piperazine-derived designer drug, which has been reported for the first time in the Reitox Early warning system through a Reporting Form in November 2006 by France. Systematic chemical name 1-(4-chlorophenyl)piperazine Other names 1-(4-chlorophenyl)piperazine is the systematic chemical name but the substance is better known by one of its codenames pCPP (where ‘p’ stands for para, signifying the fourth position of the chlorine atom on the phenyl ring, and ‘CPP’ stands for chlorophenylpiperazine), 4CPP or 4Cl-PP. Depending on the position of the chlorine atom, other possible CPP isomers are 1-(3-chlorophenyl)piperazine (for meta- CPP) and 1-(2-chlorophenyl)piperazine, (codenames oCPP (for ortho-CPP), 2CPP or 2Cl-PP). As use of codenames could be confusing, they should be used only for initial orientation. B. Alerts Alerts The Belgian Early Warning System Drugs (BEWSD) issued an alert in september 2016 concerning a tablet containing amphetamine and pCPP. Reports to EMCDDA Latvia: In its EWS Report for the 1st half of 2009 the NFP reported 12 seizures totalizing 952 tablets and 2 seizures of 3.2532g powder. Sweden: In its EWS Report for the 1st half of 2009 the NFP reported 1 seizure of 0,73g powder; 1 seizure of 5 capsules; 25 seizures of tablets, 249 units; 4 seizures of tablets, 497 units. (reported as mCPP or pCPP). Switzerland: On 25 July 2009 an ecstasy tablet containing pCPP (36.24mg) and mCPP was reported in Switzerland for the first time. Latvia: In its EWS Report for the 1st half of 2008 the NFP reported 5 seizures of 22 tablets. Bulgaria: In March 2007 the NFP reported 1 seizure of 49.385 g white tablets with Rolls Royce logo seized in Asenovgrad in 2006. Tablets containing 5% MDMA. Bulgaria: In March 2007 the NFP reported 1 seizure of 64 white tablets with "Crocodile" logo seized in Kardzhali in 2006. Bulgaria: In March 2007 the NFP reported 1 seizure of 1 white tablet with Rolls Royce logo seized in Sofia in 2006. Tablet containing 6% MDMA. Bulgaria: In March 2007 the NFP reported 1 seizure of 1 white tablet with Mitsubishi logo seized in Varna in 2006. Tablet containing 1% MDMA and caffeine. Bulgaria: In March 2007 the NFP reported 1 seizure of 3,55 g white tablets with Mitsubishi logo seized in Varna in 2006. Tablets containing 27% MDMA. Bulgaria: In March 2007 the NFP reported 1 seizure of 260 white tablets, "heart" logo, seized in Varna in 2006. Tablets containing 1% MDMA. Bulgaria: In March 2007 the NFP reported 1 seizure of 3 white tablets, Mitsubishi logo seized in Sofia in 2006. France: In November 2006 the NFP reported a collected sample of powder. It was collected in Lyon in September and was sniffed in a party. C. Pictures Recent collected sample in Belgium D. Clinical information Usage A number of piperazine derivatives have been reported as recreational drugs. Only limited investigations have been conducted on the proprerties of pCPP. The isomers, predominantly mCPP, have been used as surreptitious substitutes for MDMA. Scientific research has demonstrated pCPP to have serotonergic effects, likely acting as a non-selective serotonin receptor agonist and/or releasing agent. Health risks headache, nausea, severe halucinations, drunkenness. following the recreational use of piperazine party drugs, users may experience periods of exertion, lack of sleep or dehydratation. Other uses / E. Legal status Belgium: controlled as of 22 October 2006 F. Chemistry Other chemical names and variants Para-chlorophenylpiperazine (see also code names) Chemical Abstracts Service (CAS) registry number pCPP (CAS# 38212-33-8) Molecular information The piperazine-derived designer drugs could be divided into: (a) benzylpiperazines – including 1-benzyl-piperazine (BZP); and 1-(3,4- methylenedioxybenzyl)piperazine (MDBP); and (b) phenylpiperazines – including (1-(4-methoxyphenyl)-piperazine (MeOPP); 1-(3- trifluoromethylphenyl)-piperazine (TFMPP); 1-(3-chlorophenyl)piperazine (mCPP) and 1-(4-chlorophenyl)piperazine (pCPP). Molecular structure: Molecular formula: C10H13ClN2 Molecular weight: 196.68 Identification and analytical profile See annex: "Analytical profiles of the piperazines", from the LTG (formerly known as the London Toxicology Group) G. References / Analytical profiles of the piperazines Over the past few months (Autumn 2006) members of LTG have become aware of an increasing number of piperazine compounds sold on websites as “herbal ecstasy”. They are often promoted as a legal alternative to MDMA, sometimes as a “harm minimisation” strategy. None of the compounds are licensed medicines or have been evaluated for their safety. The health consequences of the widespread availability are beginning to emerge with reports of hospitalisations and involvement in road accidents. This monograph presents brief analytical profiles of the piperazine derivatives found in “illicit” tablets and capsules in the UK. Not all the compounds listed have been found in products but are presented because they are positional isomers of those that have. Isomers that are not resolved by GC/MS may be differentiated by HPLC with UV diode array detection because the UV absorption spectra vary. Analytical standards of all the compounds are available commercially from Sigma Aldrich, the catalogue numbers are provided in the table. Some compounds are only available as free bases, for others the hydrochloride salts are also available. Some immunoassays that target methylamfetamine also detect some of the piperazines. Dilutions of a 1mg/mL solution of the compounds in methanol were made in water for the evaluations of the immunoassay unit test devices. Thanks are due to Alan Freke of Dade Behring for donation of the Syva RapidTest d.a.u. devices. The compounds NN 1-benzylpiperazine BZP A C H N mw 176 11 16 2, Sigma Aldrich 13815-25G-F 1-(4-fluorophenyl)piperazine B C10H13FN2, mw 180 pFPP NN F Sigma Aldrich 19133-7 1-(3-trifluoromethylphenyl) piperazine m-trifluoromethylphenylpiperazine NN C C11H13F3N2, mw 230 TFMPP 1-(α,α,α-trifluoro-m-tolyl)piperazine CF Sigma Aldrich T8948 (HCl) 3 1-(3-methylphenyl)piperazine NN D C11H16N2, mw 176 mMPP Sigma Aldrich R435376 (diHCl) CH 3 1-(4-methylphenyl)piperazine E C11H16N2, mw 176 pMPP NN CH3 Sigma Aldrich 71868-5G-F 1-(2-chlorophenyl)piperazine NN F C10H13ClN2, mw 196.5 oCPP Sigma Aldrich C67605 (HCl) Cl 1-(2-methoxyphenyl)piperazine NN G C11H16N2O, mw 192 oMeOPP Sigma Aldrich M22601-5G (HCl) CH O 3 1-(3-chlorophenyl)piperazine NN H C10H13ClN2, mw 196.5 mCPP Sigma Aldrich 125180-5G (HCl) Cl 1-(4-methoxyphenyl)piperazine NN OCH3 I C11H16N2O, mw 192 pMeOPP Sigma Aldrich 571415-1G (diHCl) 1-(4-chlorophenyl)piperazine J C10H13ClN2, mw 196.5 pCPP NN Cl Sigma Aldrich C68008 1,4-dibenzylpiperazine NN K C18H22N2, mw 266.4 DBZP Sigma Aldrich S383937-1EA (diHCl) GC/MS Samples were analysed on a Shimadzu QP2010 gas chromatograph mass spectrometer with an HP5MS column (30m x 0.25mm, 0.50µm). Column oven temperature 80°C Injection temperature 225°C Injection mode Split Split ratio 10:1 Carrier gas Helium Flow rate 1.0 ml/min Pressure 9.5 psi Ion source temperature 200°C Interface temperature 250°C Column oven temperature programme: Rate Final temperature Hold time - 80°C 4 minutes 40.00°C/min 290°C 10.75 minutes Chromatogram:- (x10,000,000) TIC (D),(E) I.S 8.898 I.S 10.068 1.00 (F),(G) 8.943 7.444 (B),(C) 0.75 9.325 8.554 (H),(I),(J) (A) 8.478 0.50 0.25 0.00 7.0 7.5 8.0 8.5 9.0 9.5 10.0 10.5 11.0 Retention time ID Compound Name Abbreviations (mins.) I.S. Quinoline - 7.444 A Benzylpiperazine BZP 8.478 B 1-(4-fluorophenyl)piperazine pFPP 8.554 (front) C m-trifluoromethylphenylpiperazine TFMPP 8.554 (tail) D 1-(3-methylphenyl)piperazine mMPP 8.898 E 1-(4-methylphenyl)piperazine pMPP 8.898 F 1-(2-chlorophenyl)piperazine oCPP 8.943 (front) G 1-(2-methoxyphenyl)piperazine oMeOPP 8.943 (tail) H 1-(3-chlorophenyl)piperazine mCPP 9.325 (front) I 1-(4-methoxyphenyl)piperazine pMeOPP 9.325 J 1-(4-chlorophenyl)piperazine pCPP 9.325 I.S. Pyribenzamine (tripelenamine) - 10.068
Recommended publications
  • 16.19.20 Nmac 1 Title 16 Occupational And

    16.19.20 Nmac 1 Title 16 Occupational And

    TITLE 16 OCCUPATIONAL AND PROFESSIONAL LICENSING CHAPTER 19 PHARMACISTS PART 20 CONTROLLED SUBSTANCES 16.19.20.1 ISSUING AGENCY: Regulation and Licensing Department - Board of Pharmacy. [16.19.20.1 NMAC - Rp 16.19.20.1 NMAC, 06-26-2018] 16.19.20.2 SCOPE: All persons or entities that manufacture, distribute, dispense, administer, prescribe, deliver, analyze, or conduct research using controlled substances. [16.19.20.2 NMAC - Rp 16.19.20.2 NMAC, 06-26-2018] 16.19.20.3 STATUTORY AUTHORITY: Section 30-31-11 of the Controlled Substances Act, 30-31-1 through 30-31-42 NMSA 1978, authorizes the board of pharmacy to promulgate regulations and charge reasonable fees for the registration and control of the manufacture, distribution and dispensing of controlled substances. [16.19.20.3 NMAC - Rp 16.19.20.3 NMAC, 06-26-2018] 16.19.20.4 DURATION: Permanent. [16.19.20.4 NMAC - Rp 16.19.20.4 NMAC, 06-26-2018] 16.19.20.5 EFFECTIVE DATE: June 26, 2018, unless a different date is cited at the end of a section. [16.19.20.5 NMAC - Rp 16.19.20.5 NMAC, 06-26-2018] 16.19.20.6 OBJECTIVE: The objective of Part 20 of Chapter 19 is to protect the public health and welfare of the citizens of New Mexico by controlling and monitoring access to controlled substances and to give notice of the board’s designation of particular substances as controlled substances. [16.19.20.6 NMAC - Rp 16.19.20.6 NMAC, 06-26-2018] 16.19.20.7 DEFINITIONS: [RESERVED] [16.19.20.7 NMAC - Rp 16.19.20.7 NMAC, 06-26-2018] 16.19.20.8 REGISTRATION REQUIREMENTS: Persons required to register: A.
  • Mass Spectral, Infrared and Chromatographic Studies on Designer Drugs of the Piperazine Class by Karim M. Hafiz Abdel-Hay a Diss

    Mass Spectral, Infrared and Chromatographic Studies on Designer Drugs of the Piperazine Class by Karim M. Hafiz Abdel-Hay a Diss

    Mass Spectral, Infrared and Chromatographic Studies on Designer Drugs of the Piperazine Class by Karim M. Hafiz Abdel-Hay A dissertation submitted to the Graduate Faculty of Auburn University in partial fulfillment of the requirements for the degree of Doctor of Philosophy Auburn, Alabama May 7, 2012 Approved by C. Randall Clark, Chair, Professor of Pharmacal Sciences Jack DeRuiter, Professor of Pharmacal Sciences Forrest Smith, Associate Professor of Pharmacal Sciences Angela Calderon, Assistant Professor of Pharmacal Sciences Abstract The controlled drug 3,4-methylenedioxybenzylpiperazine (3,4-MDBP) has regioisomeric and isobaric substances of mass equivalence, which have similar analytical properties and thus the potential for misidentification. The direct regioisomers of 3,4-MDBP include the 2,3- methylenedioxy substitution pattern and the indirect regioisomers include the three ring substituted methoxybenzoylpiperazines. The ethoxy and methoxymethyl ring substituted benzylpiperazines constitute the major category of isobaric substances evaluated in this study. The direct and indirect regioisomers of 3,4-MDBP and also isobaric substances related to MDBP were synthesized and compared to 3,4-MDBP by using gas chromatographic and spectrophotometric techniques. The GC-MS studies of the direct regioisomers and isobaric substances of 3,4-MDBP indicated that they can not be easily differentiated by mass spectrometry. The synthesized compounds were converted to their perfluoroacyl derivatives, trifluoroacetyl (TFA), pentafluoropropionyl amides (PFPA) and heptafluorobutryl amides (HFBA), in an effort to individualize their mass spectra and to improve chromatographic resolution. Derivatized 3,4-MDBP was not distingushed from its derivatized regioisomers or isobars using mass spectrometry. No unique fragment ions were observed for the various regioisomeric and the isobaric compounds.
  • Alcohol and Drug Abuse Subchapter 9 Regulated Drug Rule 1.0 Authority

    Alcohol and Drug Abuse Subchapter 9 Regulated Drug Rule 1.0 Authority

    Chapter 8 – Alcohol and Drug Abuse Subchapter 9 Regulated Drug Rule 1.0 Authority This rule is established under the authority of 18 V.S.A. §§ 4201 and 4202 which authorizes the Vermont Board of Health to designate regulated drugs for the protection of public health and safety. 2.0 Purpose This rule designates drugs and other chemical substances that are illegal or judged to be potentially fatal or harmful for human consumption unless prescribed and dispensed by a professional licensed to prescribe or dispense them, and used in accordance with the prescription. The rule restricts the possession of certain drugs above a specified quantity. The rule also establishes benchmark unlawful dosages for certain drugs to provide a baseline for use by prosecutors to seek enhanced penalties for possession of higher quantities of the drug in accordance with multipliers found at 18 V.S.A. § 4234. 3.0 Definitions 3.1 “Analog” means one of a group of chemical components similar in structure but different with respect to elemental composition. It can differ in one or more atoms, functional groups or substructures, which are replaced with other atoms, groups or substructures. 3.2 “Benchmark Unlawful Dosage” means the quantity of a drug commonly consumed over a twenty-four hour period for any therapeutic purpose, as established by the manufacturer of the drug. Benchmark Unlawful dosage is not a medical or pharmacologic concept with any implication for medical practice. Instead, it is a legal concept established only for the purpose of calculating penalties for improper sale, possession, or dispensing of drugs pursuant to 18 V.S.A.
  • Potential Doping Substances Detected in Boosters in Poland

    Potential Doping Substances Detected in Boosters in Poland

    Kwiatkowska, D1), Pokrywka, A1), Jarek, A1), Gorczyca, D 1) Potential doping substances detected in boosters in Poland 1)Department of Anti-Doping Research, Institute of Sport, Warsaw, Poland Abstract In 2003 the World Anti-Doping Agency (WADA) took responsibility for the List of substances and methods prohibited in sport (the Prohibited List). Since that moment the list has been regularly updated, and all changes, based mainly on scientific research, have been preceded by numerous consultations with representatives of the sport and medicine. By publishing a new version of the Prohibited List every year and by enlisting numerous examples of prohibited substances WADA fulfilled partly the need of publishing a complete list of prohibited substances. However, the Prohibited List still has an open character. In spite of the examples of prohibited substances or methods in particular groups, some additional substances, which are not located on the list but are characterized by “a similar chemical structure or similar biological effect(s)”, can be considered as doping. Introduction In recent years several well-known Polish athletes have personally found out what this definition means. In their urine samples 4-methyl-2-hexaneamine and beta- methylphenylethylamine were detected during the doping control. These substances, which were found also in dietary supplements, were not mentioned on the WADA Prohibited List at the time. However, both substances were recognized by WADA as banned in sport because of chemical similarity to the structure of tuaminoheptane and amphetamine. Potential doping substances can be also ingredients of boosters (legal highs, smarts, party pills). This work presents the results of analyses of several products from Polish market Materials and Methods The laboratory analysed 50 boosters available on the polish market.
  • Model Scheduling New Novel Psychoactive Substances

    Model Scheduling New Novel Psychoactive Substances

    Model Scheduling New/Novel Psychoactive Substances Act September 2018 (original version published in 2014). This project was supported by Grant No. G1799ONDCP03A, awarded by the Office of National Drug Control Policy. Points of view or opinions in this document are those of the author and do not necessarily represent the official position or policies of the Office of National Drug Control Policy or the United States Government. © 2018. NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. This document may be reproduced for non- commercial purposes with full attribution to the National Alliance for Model State Drug Laws. Please contact Jon Woodruff at [email protected] or (703) 836-7496 with any questions about the Model Language. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE 1 FOR MODEL STATE DRUG LAWS, 1335 North Front Street, First Floor, Harrisburg, PA, 17102-2629. Model Scheduling New/Novel Psychoactive Substances Act Table of Contents 3 Policy Statement and Background 5 Highlights 6 Section I – Short Title 6 Section II – Purpose 6 Section III – Synthetic Cannabinoids 12 Section IV – Substituted Cathinones 18 Section V – Substituted Phenethylamines 22 Section VI – N-benzyl Phenethylamine Compounds 24 Section VII – Substituted Tryptamines 27 Section VIII – Substituted Phenylcyclohexylamines 28 Section IX – Fentanyl Derivatives 37 Section X – Unclassified NPS © 2018. NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. This document may be reproduced for non- commercial purposes with full attribution to the National Alliance for Model State Drug Laws. Please contact Jon Woodruff at [email protected] or (703) 836-7496 with any questions about the Model Language.
  • Piperazine Derivatives As Dangerous Abused Compounds

    Piperazine Derivatives As Dangerous Abused Compounds

    Acta Pharm. 70 (2020) 423–441 Review https://doi.org/10.2478/acph-2020-0035 Piperazine derivatives as dangerous abused compounds ANNA WELZ* Piperazine derivatives are a group of compounds with a MARCIN KOBA psychostimulant effect. They are an alternative to illegal drugs. They are being searched for recreational use due to Department of Toxicology their psychoactive and hallucinogenic effects. The high Faculty of Pharmacy popularity of these compounds can be noticed all over the Collegium Medicum Nicolaus world due to easy purchase, lack of legal regulations and Copernicus University incorrect assessment of the safety of use. The recreational Bydgoszcz, Poland use of piperazine derivatives can often result in chronic and acute health problems and additionally with unpre- dictable remote effects. It is also common to take mixtures of psychoactive compounds. This hinders the correct diagnosis and treatment of patients with poisoning. The presented work is an illustration of the wide problem of pipe razine derivatives abuse. The health effects and the possi bility of identifying these compounds in preparations and biological material are described. Accepted December 3, 2019 Keywords: piperazine derivatives, designer drugs, benzyl- Published online December 16, 2019 piperazine, phenylpiperazine, addiction INTRODUCTION Available literature data indicates a growing interest in new psychoactive substances (NPS) around the world (1, 2). These products, often called designer drugs, can be divided into three main groups: piperazine derivatives, ketoarylamines and synthetic cannabi- noids. The modified chemical structures of these compounds aim to mimic the pharmaco- logical effects of illicit drugs and trigger potential abuses. The problem of today is consumers experimenting with these substances in order to achieve a specific benefit (3, 4).
  • Controlled Substances List (Adopted by Alabama State Board of Health on January 20, 2021, Effective January 20, 2021)

    Controlled Substances List (Adopted by Alabama State Board of Health on January 20, 2021, Effective January 20, 2021)

    1 Controlled Substances List (Adopted by Alabama State Board of Health on January 20, 2021, effective January 20, 2021) Schedule I (a) Schedule I shall consist of the drugs and other substances, by whatever official name, common or usual name, or brand name designated, listed in this section. Each drug or substance has been assigned the DEA Controlled Substances Code Number set forth opposite it. (b) Opiates. Unless specifically excepted or unless listed in another schedule, any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters and ethers, whenever the existence of such isomers, esters, ethers and salts is possible within the specific chemical designation (for purposes of 3-methylthiofentanyl only, the term isomer includes the optical and geometric isomers): (1) Acetyl-alpha-methylfentanyl (N-[1-[1-methyl-2-phenethyl]-4-piperidinyl]- N-phenylacetamide -------------------------------------------------------------------- 9815 (Federal Control Nov. 29, 1985; State Dec. 29, 1985) (2) Acetylmethadol ------------------------------------------------------------------------- 9601 (3) AH-7921 (3,4-dichloro-N-[(1-dimethylamino)cyclohexylmethyl] benzamide -------------------------------------------------------------------------------- 9551 Federal Control May 16, 2016; State June 15, 2016 (4) Allylprodine ----------------------------------------------------------------------------- 9602 (5) Alphacetylmethadol --------------------------------------------------------------------- 9603 (6) Alphameprodine
  • EMCDDA RISK ASSESSMENTS Report on the Risk Assessment of BZP in the Framework of the Council Decision on New Psychoactive Substances

    EMCDDA RISK ASSESSMENTS Report on the Risk Assessment of BZP in the Framework of the Council Decision on New Psychoactive Substances

    ISSN 1725–4485 Report on the risk assessment of BZP in the framework of the Council decision on new psychoactive substances TD-AK-08-008-EN-C About the EMCDDA The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) is one of the European Union’s decentralised agencies. Established in 1993 and based in Lisbon, it is the central source of comprehensive information on drugs and drug addiction in Europe. The EMCDDA collects, analyses and disseminates factual, objective, reliable and comparable information on drugs and drug addiction. In doing so, it provides its audiences with an evidence- based picture of the drug phenomenon at European level. EMCDDA The Centre’s publications are a prime source of information for a wide range of audiences including policymakers and their RISK ASSESSMENTS advisors, professionals and researchers working in the drugs field and, more broadly, the media and general public. EMCDDA risk assessments are publications examining the health and social risks of individual synthetic drugs on the basis of research carried out by the agency and its partners. Report on the risk assessment of BZP in the framework of the Council decision on new psychoactive substances EMCDDA RISK ASSESSMENTS 8 2531366_2008.2642_COVER.indd 1 82/19/09 08:58:26 How to obtain EU publications Our priced publications are available from EU Bookshop (http://bookshop.europa.eu), where you can place an order with the sales agent of your choice. The Publications Office has a worldwide network of sales agents. You can obtain their contact details by sending a fax to (352) 29 29-42758.
  • The Development of Microfluidic Devices for the Rapid Isolation And

    The Development of Microfluidic Devices for the Rapid Isolation And

    The author(s) shown below used Federal funds provided by the U.S. Department of Justice and prepared the following final report: Document Title: The Detection of Date Rape Drugs by Capillary Electrochromatography Author(s): Bruce McCord Document No.: 210417 Date Received: June 2005 Award Number: 2002-MU-MU-K002 This report has not been published by the U.S. Department of Justice. To provide better customer service, NCJRS has made this Federally- funded grant final report available electronically in addition to traditional paper copies. Opinions or points of view expressed are those of the author(s) and do not necessarily reflect the official position or policies of the U.S. Department of Justice. The Detection of Date Rape Drugs by Capillary Electrochromatography #2002-MUMU-K002 Bruce McCord, PI, Ohio University Current address: Department of Chemistry, Florida International University, Miami, FL 33199 [email protected] Portions of this report were taken from the doctoral dissertations of Sandra Bishop and Ahmed Alnajjar, Ohio University, 2004 1. Abstract Drug facilitated sexual assault is becoming an increasing problem throughout the United States. Victims of this crime often do not report to authorities and when they do, time may have passed to the point where detection of the drug in their system becomes difficult. In addition, many of the drugs used are difficult to detect using standard immunoassay techniques. As a result, more advanced methods such as gas chromatography with nitrogen phosphorus detection must be used, In recent years, a number of forensic laboratories have begun to use capillary electrophoresis (CE) as an alternative to GC/NPD screening for this purpose.
  • N-Benzylpiperazine (BZP)

    N-Benzylpiperazine (BZP)

    N‐Benzylpiperazine (BZP) Critical Review Report Agenda item 4.2 Expert Committee on Drug Dependence Thirty‐sixth Meeting Geneva, 16‐20 June 2014 36th ECDD (2014) Agenda item 4.2 N‐Benzylpiperazine (BZP) Page 2 of 30 36th ECDD (2014) Agenda item 4.2 N‐Benzylpiperazine (BZP) Acknowledgements This report has been drafted under the responsibility of the WHO Secretariat, Essential Medicines and Health Products, Policy Access and Rational Use Unit. The WHO Secretariat would like to thank the following people for their contribution in producing this critical review report: Dr Simon Elliott, United Kingdom (literature review and drafting), Dr Caroline Bodenschatz, Switzerland (editing) and Mr David Beran, Switzerland (questionnaire report drafting). Page 3 of 30 36th ECDD (2014) Agenda item 4.2 N‐Benzylpiperazine (BZP) Page 4 of 30 36th ECDD (2014) Agenda item 4.2 N‐Benzylpiperazine (BZP) Contents Summary.............................................................................................................................................................................. 7 1. Substance identification ............................................................................................................................................ 8 A. International Nonproprietary Name (INN) ........................................................................................................ 8 B. Chemical Abstract Service (CAS) Registry Number .......................................................................................... 8 C. Other
  • 6Ar,9S)-Delta-10-THC 1 Cp-LSD 1-(3-Chloro-4-Fluorophenyl

    6Ar,9S)-Delta-10-THC 1 Cp-LSD 1-(3-Chloro-4-Fluorophenyl

    Analytes (6aR,9R)-delta-10-THC (6aR,9S)-delta-10-THC 1 cP-LSD 1-(3-Chloro-4-fluorophenyl)piperazine 1-(4-Bromophenyl)piperazine 1,4-Butanediol 1,4-Dibenzylpiperazine 11-Ketotestosterone 17-Alpha-Estradiol 17-Alpha-Methyltestosterone 17-Beta-Estradiol 17-beta-Hydroxyandrosta-4,6-dien-3-one (6-Dehydrotestosterone) 19-Nor-4-androstene-3,17-dione 1-Methyl-4-benzylpiperazine (MBZP) 1-Naphthylamine 1P-LSD 2,3-Dichlorophenylpiperazine 2,3-difluoro U-47700 2,3-Methylenedioxymethcathinone 2,5-dimethoxy Fentanyl 25B-NBOH di-acetyl derivative 25B-NBOH mono-acetyl derivative 25B-NBOMe 25C-NBOH di-acetyl derivative 25C-NBOH mono-acetyl derivative 25C-NBOMe 25D-NBOMe 25E-NBOH di-acetyl derivative 25E-NBOH mono-acetyl derivative 25H-NBOMe 25H-NBOMe imine analog 25I-NBOMe 25I-NBOMe imine analog 25N-NBOMe 2-bromo-4,5-Dimethoxyphenethylamine 2C-B (2,5-Dimethoxy-4-bromophenethylamine) 2C-B FLY formyl artifact 2C-B mono-acetyl derivative 2C-B-FLY (8-Bromo-2,3,6,7-benzo-dihydro-difur-ethylamine) 2C-C (2,5-Dimethoxy-4-chlorophenethylamine) Analytes 2C-C (2,5-Dimethoxy-4-chlorophenethylamine) mono-acetyl derivative 2C-C formyl artifact 2C-D (2,5-Dimethoxy-4-methylphenethylamine) 2C-D formyl artifact 2C-E (2,5-Dimethoxy-4-ethylphenethylamine) 2C-E (2,5-Dimethoxy-4-ethylphenethylamine) mono-acetyl derivative 2C-E formyl artifact 2C-H (2,5-Dimethoxyphenethylamine) 2C-H formyl artifact 2-Chloroethcathinone 2-Chloromethcathinone 2-chloro-N,N-dimethylcathinone 2C-I (2,5-Dimethoxy-4-iodophenethylamine) 2C-I (2,5-Dimethoxy-4-iodophenethylamine) mono-acetyl derivative
  • Laboratory Licensure As of July 2003

    Laboratory Licensure As of July 2003

    Drug Identification Scope of Testing Effective June 4, 2021 6aR,9R)-delta-10-THC 3,4-Methylenedioxy U-47700 (6aR,9S)-delta-10-THC 3,4-Methylenedioxy-a-Pyrrolidinohexanophenone (MDPHP)^ 1 cP-LSD ^ 3,4-Methylenedioxy-N,N-diethylcathinone^ 1-(3-Chloro-4-fluorophenyl)piperazine^ 3,4-Methylenedioxy-N-benzylcathinone^ 1-(4-Bromophenyl)piperazine^ 3,4-Methylenedioxy-N-tert-butylcathinone^ 1,4-Butanediol 3,4-tetramethylene-alpha-Pyrrolidinovalerophenone^ 1,4-Dibenzylpiperazine 3-Aminopyridine 11-Ketotestosterone 3-Bromomethcathinone^ 17-Alpha-Estradiol 3-Chloroethcathinone^ 17-Alpha-Methyltestosterone 3-Chloromethcathinone^ 17-Beta-Estradiol 3-chloro-N,N-dimethylcathinone^ 17-beta-Hydroxyandrosta-4,6-dien-3-one (6- 3-ethoxy-4-methoxy N,N-Diethylpentedrone^ Dehydrotestosterone) 3-Ethylmethcathinone^ 19-Nor-4-androstene-3,17-dione 3-Fluoroamphetamine^ 1-Methyl-4-benzylpiperazine (MBZP)^ 3-Fluoroethamphetamine^ 1-Naphthylamine 3-Fluoromethamphetamine^ 1P-LSD 3-Fluorophenmetrazine^ 2,3-Dichlorophenylpiperazine^ 3-FMC (3-Fluoromethcathinone)^ 2,3-difluoro U-47700 3-hydroxy PCE^ 2,3-Methylenedioxymethcathinone^ 3-hydroxy PCP^ 2,5-dimethoxy Fentanyl 3-hydroxy Phenazepam/Cinazepam 25B-NBOH^ 3-MEC (3-Methylethcathinone)^ 25B-NBOMe^ 3-MeO-PCE (3-Methoxyeticyclidine)^ 25C-NBOH^ 3-MeO-PCP^ 25C-NBOMe^ 3-methoxy-4-ethoxy N,N-Diethylpentedrone^ 25D-NBOMe^ 3-Methoxymethamphetamine^ 25E-NBOH^ 4-acetoxy DMT^ 25H-NBOMe^ 4-acetoxy MALT^ 25H-NBOMe imine analog^ 4-acetoxy MET^ 25I-NBOMe^ 4-acetoxy MPT^ 25I-NBOMe imine analog^ 4-Aminopyridine 25N-NBOMe^ 4-Anilinopiperidine